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Available online 10 August 2016Purpose: In Gaucher disease, diminished activity of the lysosomal enzyme, acid β-glucosidase, leads to accumu-
lation of glucosylceramides and related substrates, primarily in the spleen, liver, and bone marrow. Eliglustat
is an oral substrate reduction therapy approved in the European Union and the United States as a ﬁrst-line treat-
ment for adults with type 1 Gaucher disease who have compatible CYP2D6metabolism phenotypes. A European
Advisory Council of experts in Gaucher disease describes the characteristics of eliglustat that are distinct from
enzyme augmentation therapy (the standard of care) and miglustat (the other approved substrate reduction
therapy) and recommends investigations and monitoring for patients on eliglustat therapy within the context
of current recommendations for Gaucher disease management.
Results: Eliglustat is a selective, potent inhibitor of glucosylceramide synthase, the enzyme responsible for
biosynthesis of glucosylceramides which accumulate in Gaucher disease. Extensive metabolism of eliglustat by
CYP2D6, and, to a lesser extent, CYP3A of the cytochrome P450 pathway, necessitates careful consideration of
the patient's CYP2D6 metaboliser status and use of concomitant medications which share metabolism by these
pathways. Guidance on speciﬁc assessments and monitoring required for eliglustat therapy, including an
algorithm to determine eligibility for eliglustat, are provided.
Conclusions: As a ﬁrst-line therapy for type 1 Gaucher disease, eliglustat offers eligible patients a daily oral ther-
apy alternative to biweekly infusions of enzyme therapy. Physicians will need to carefully assess individual
Gaucher patients to determine their appropriateness for eliglustat therapy. The therapeutic response to eliglustat
and use of concomitant medications will require long-term monitoring.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Enzyme replacement/augmentation therapy
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European Union (2015) and the United States (2014) as a ﬁrst-line
treatment for adults with type 1 Gaucher disease who are extensive,
intermediate, or poor metabolisers, as predicted by genotyping the
cytochrome P450 CYP2D6 locus [1]. It joins enzyme replacement therapy
(ERT) as a ﬁrst-line therapy for the disease. As an oral therapy, eliglustat
also offers advantages over ERT with respect to time spent on therapy;
compatibility of treatment with job, family, and social commitments;
and, probably, improved quality of life.
Venous infusions of ERT have been in wide use for more than two
decades. The therapy is usually well tolerated and considered safe, and
infusion at the patient's home is possible in those countries where
home infusions are supported by the health care system. ERT is typically
prescribed by physicians experienced in treating Gaucher disease. Its
prescription requires consideration of the patient's body weight and ti-
tration to therapeutic efﬁcacy. As a result of its genetically determined
metabolism in the liver, eliglustat requires individual adaptation of the
dose and careful supervision of concomitant medications.
In this review, the distinctive characteristics of eliglustat are set out,
together with the necessary basic investigations and monitoring
required during maintenance of this therapy. All other aspects of the
current recommendations for management of Gaucher disease [2–5]
remain unchanged. The authors are members of a European Advisory
Council consisting of leading experts in Gaucher disease convened
by Sanoﬁ Genzyme to consider the appropriate use of eliglustat in
the treatment of adults with type 1 Gaucher disease. This position
statement reﬂects the consensus reached by the Council based on the
European product label for eliglustat and their collective clinical experi-
ence treating patients with Gaucher disease. An independently con-
vened panel of United States (US) experts in Gaucher disease recently
published recommendations for use of eliglustat which are consistent
with the US product label, including different dosing regimens in the
context of clinical practice in the US [6].
2. Current management of Gaucher disease
Gaucher disease is an inherited disease due to mutations in both
alleles of the acid β-glucosidase gene resulting in deﬁcient activity of
the lysosomal enzyme, acid β-glucosidase [7,8]. The consequent
accumulation of its substrates, notably glucosylceramides, primarily in
the spleen, liver, and bone marrow can lead to progressive and debilitat-
ing manifestations, including spleen and liver enlargement, anaemia,
thrombocytopenia, pulmonary disease, immune dysfunction, bone pain,
osteoporosis, avascular necrosis (osteonecrosis), osteolytic lesions and
destruction of joints [2,3,7–13]. Types 2 and 3 Gaucher disease also affect
the central nervous system. Type 1 Gaucher disease, the so-called non-
neuronopathic form, is the most common form in the United States and
Northwestern European populations, affecting an estimated 1 in 40,000
to 1 in 60,000 individuals [14]; there is a higher prevalence among
Ashkenazi Jews [8].
The diagnosis of Gaucher disease is conﬁrmed by demonstrating de-
creased acid β-glucosidase activity in leukocytes and/or by molecular
analysis of the GBA1 gene to identify two mutations plausibly in trans
either previously associated with the disease or judged to be disabling
for catalytic function or enzyme integrity [2,15]. In the case of inconclu-
sive residual enzyme activity, the presence of two knownmutant alleles
in the GBA1 gene is diagnostic [15]. Enzyme therapy with imiglucerase
(Cerezyme, Sanoﬁ Genzyme, Cambridge, MA, USA) has, over more
than 20 years, proved to very effective in Gaucher disease. Two other
ERTs (velaglucerase alpha [VPRIV], Shire Human Genetic Therapies,
Lexington, MA, USA, and taliglucerase alfa [ELELYSO], Pﬁzer Labs, New
York, NY, USA) have also been approved and are used widely in clinical
practice, although taliglucerase alfa is not approved in Europe. Early
treatment with imiglucerase for patients with symptomatic diseasehas been shown to improve outcomes, including regression or amelio-
ration of organomegaly, reversal of anaemia and thrombocytopenia,
amelioration of bone pain and bone crises [16], reversal of osteopenia
[10], prevention of avascular necrosis (osteonecrosis) [9], improved
bonemarrow burden score (at higher doses) [17], and improved quality
of life [18]. Despite the success of enzyme therapy in treating Gaucher
disease, the treatment has limitations, including disease in the skeleton
and lungs, which may be refractory despite long-term treatment [19].
Substrate reduction therapy represents an alternative stratagem for
ameliorating the effects of Gaucher disease by rebalancing the rate of
synthesis of glucosylceramideswith their impaired breakdown.Where-
as administration of recombinant human acid β-glucosidase augments
the endogenous enzyme activity in the patient to enhance the break-
down of accumulated glucosylceramides in the lysosomal compartment
of macrophages, substrate reduction therapy inhibits the enzyme
glucosylceramide synthase, thereby slowing the over-production of
glucosylceramides relative to their rate of recycling in the lysosomal
compartment. The oral substrate reduction therapy miglustat (Zavesca,
Actelion Pharmaceuticals, Allschwil, Switzerland) has been available in
Europe since approval in 2002; however, due to its low to medium
efﬁcacy in Gaucher disease and considerable gastrointestinal and
neurologic side effects, it is approved in the European Union only as a
second-line therapy for patients unsuitable for ERT. Eliglustat (Cerdelga,
Sanoﬁ Genzyme, Cambridge, MA, USA), a potent and selective inhibitor
of glucosylceramide synthase,was approved in Europe in 2015 as aﬁrst-
line therapy for adults with type 1 Gaucher disease who are genotyped
for CYP2D6 variants and predicted to be extensive, intermediate, or
poor metabolisers (categories which apply to more than 90% of type 1
Gaucher patients). Unlike the iminosugar miglustat, eliglustat is a cer-
amide analogue that inhibits UDP-glucosylceramide synthase without
inhibiting intestinal disaccharidases [20,21], thereby avoiding the
frequent gastrointestinal side effects encountered with miglustat
[22–24]. Miglustat achieves signiﬁcant distribution in the brain, but is
not effective in neuronopathic Gaucher disease [25] andmay cause neu-
rologic side effects in type 1 Gaucher disease [22,24]. This is avoided
with eliglustat because the multidrug transporter, Pgp-1, prevents
eliglustat accumulation in the brain [20,21,26]. As a small molecule
with a widespread tissue distribution, eliglustat may prove to be effec-
tive at “sanctuary sites” of disease, for example in bone and lung,
which are not accessible to treatment with therapeutic enzyme prepa-
rations [19]. Furthermore, oral administration of eliglustat provides an
advantage to patients when compared with regular intravenous
infusions of enzyme therapy (typically given every 2 weeks).
Thus far, 219 patientswith type 1 Gaucher disease have been treated
with eliglustat in the completed Phase 2 and 3 clinical trials (Table 1).
Administration of eliglustat induced clinically meaningful improve-
ments in platelet counts and haemoglobin concentration, spleen and
liver volumes, and bone outcomes in previously untreated patients
[27–29], which have been maintained up to 18 months in the Phase 3
ENGAGE trial [30] and 4 years in the Phase 2 trial [31]. In patients
whose disease had been stabilised with ERT before switching to
eliglustat, improved haematological, visceral and bone parameters
remained stable after 12 months on eliglustat [32], with improvements
maintained up to 2 years [33]. Among 18 patients on eliglustat for
18 months in the ENGAGE trial, mean BMD T-score of the lumbar
spine increased from baseline by 0.19 andmean BMD Z-score increased
by 0.26 [30]. The 15patients receiving 4 years of eliglustat therapy in the
Phase 2 trial had increases from baseline of 0.7 in both T-score and
Z-score of lumbar spine [34]. Longer-term data are needed to fully
evaluate eliglustat's effects on bone disease.
3. Eliglustat dosing and drug interactions
Eliglustat is metabolised by enzymes of the cytochrome P450
pathway, preferentially CYP2D6, and, to a lesser extent, CYP3A. Recom-
mendations for eliglustat dosing based on predicted CYP2D6metaboliser
Table 1
Clinical trials of eliglustat.
Treatment-naïve patients Patients switching from ERT
Phase 2 [27] Phase 3 [29] Phase 3 [32]
Eliglustat (N = 26) Eliglustat (N = 20) Placebo (N = 20) Eliglustat (N = 106) Imiglucerase (N = 53)
Primary endpoint Improvement from baseline to 12 months
in ≥2 of 3 main efﬁcacy parameters
(spleen volume, haemoglobin
level, and platelet count)a
Mean percentage change in spleen volume
by MRI from baseline to 9 months
Percentage of patients whose haematological
parameters and organ volumes remained stable
after 12 monthsb
Primary endpoint met Yes Yes Yesc
91% (20/22) of completers Treatment difference:−30% Stable: 85% Stable: 94%
Components of primary
endpoint
12-month change from baseline: 9-month change from baseline: Stable after 12 months:
Spleen volume −38.5% −27.8% +2.3% 96% 100%
Liver volume −17.0% −5.2% +1.4% 96% 94%
Haemoglobin +1.62 mg/dL +0.69 g/dL −0.54 g/dL 95% 100%
Platelet count +40.3% +32.0% −9.1% 93% 100%
Bone marrow burden score Not assessed Baseline: 10.9
9 months: 9.8d
Baseline: 9.8
9 months: 9.8
Baseline: 8.25
12 months: 8.10
Baseline: 8.28
12 months: 8.06
Long-term follow-up 48-month change from
baseline [31]
18-month change from
baseline [30]
9-month change after
switch to eliglustate [30]
Stable at 24 months
(n = 99) [33]
Stable at 12 months after
switch to eliglustate
(n = 47) [33]
Spleen volume −63% −45% −31% 96% 97%
Liver volume −28% −11% −7.3% 96% 95%
Haemoglobin +2.3 g/dL +1.02 g/dL +0.79 g/dL 97% 100%
Platelet count +95% +58% +40% 94% 90%
Bone marrow burden score Not assessed −2.15 −0.94 Not reported Not reported
a Improvements deﬁned as: a reduction of at least 15% in spleen volume and increases of at least 0.5 g/dL in haemoglobin level and 15% in platelet count.
b Stability deﬁned as: haemoglobin concentration that did not decrease more than 1.5 g/dL, platelet count that did not decrease more than 25%, spleen volume in multiples of normal size
(MN) that did not increase more than 25%, and liver volume (MN) that did not increase more than 20% from baseline.
c In noninferiority analysis, the betweengroupsdifferencewas−8.8% (95%CI:−17.6, 4.2). The lower bound of the 95% CI for thedifference inpercentage (−17.6%)waswithin the pre-
speciﬁed threshold of−25%.
d Decrease of 1.1 for eliglustat relative to placebo (P = 0.002).
e After the 9-month primary analysis period in ENGAGE, all patients received eliglustat during the extension period. After the 12-month primary analysis period in ENCORE, all patients
received eliglustat during the extension period.
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and CYP3A are shown in Table 2. In brief, the recommended dose of
84 mg eliglustat twice daily for extensive and intermediate metabolisers
is reduced to 84 mg once daily in poor metabolisers. (Note that each
eliglustat capsule contains 100 mg eliglustat tartrate, which is equivalent
to 84 mg of eliglustat.)
Table 2 gives an overview of possible drug–drug interactions and
their effects on eliglustat dosing to avoid potential side effects arising
from these interactions. Eliglustat is contraindicated for extensive or in-
termediate metabolisers taking a strong or moderate CYP2D6 inhibitor
concomitantly with a strong or moderate CYP3A inhibitor and for poor
metabolisers taking a strong CYP3A inhibitor. Under these conditions,
the two main pathways for eliglustat metabolism are impaired and
thus substantially elevated eliglustat plasma concentrations would be
expected. Concomitant use of eliglustat with strong CYP3A inducers is
not recommended, as this substantially decreases exposure to eliglustat,
which may reduce its therapeutic efﬁcacy.
In the case of short-term use of additional medication (e.g. a 10-day
course of erythromycin), temporary cessation of eliglustat is advised but
it can be restarted when the concomitant drug regimen has been com-
pleted. As shown in Table 3, there is also potential for drug interaction
when eliglustat is taken with medications that are substrates of
P-glycoprotein (P-gp) or CYP2D6, as this could result in an increased
concentration of the concomitant drug. In this situation, the options
are either (i) monitoring the concentration of the concomitant P-gp or
CYP2D6 substrate, or (ii) reducing the dose of that drug and/or titration
according to its therapeutic efﬁcacy.
As concomitantmedications are often prescribed by general or other
physicians who share responsibility for other health matters in the
patient with Gaucher disease, it is essential that patients and each of
their physicians (and any other prescribing health professionals) are in-
formed about the potential for interactions between eliglustat and other
medications that affect CYP2D6 and CYP3A metabolism.Patients need to be informed about the correct mode of administra-
tion of eliglustat. The capsules should be swallowed whole, preferably
with water; they should not be crushed, dissolved, or opened. If a dose
of eliglustat is missed, the next prescribed dose should be taken as
scheduled, without any change (i.e. themissed dose being simply omit-
ted). Eliglustat may be taken with or without food since absorption is
unaffected. However, grapefruit and grapefruit juice should be avoided,
as contain components that inhibit CYP3Awith the potential to increase
plasma concentrations of eliglustat. Other fruits known to inhibit
CYP3A-mediated drug metabolism include pomegranate, carambola
(star fruit), and bitter orange (Seville orange) [35–37]. Licorice
(Glycyrrhiza glabra) contains principles that inhibit CYP3A4 in animal
and in vitro studies [38–40]. Although interactions between licorice
components and eliglustat have not been studied, as a precautionary
measure, it is prudent to avoid consumption of medicinal extracts,
confectionary or other preparations of this plant while taking eliglustat.
4. Initial assessments for patients taking eliglustat
Recommendations for assessment and monitoring of patients with
type 1 Gaucher diseasewere ﬁrst developed by the International Collab-
orative Gaucher Group (ICGG) in 1998 [2]; in 2004, revised recommen-
dations [4] and therapeutic goals for Gaucher patients [3] were
published. These recommendations and therapeutic goals continue to
evolve and are subject to revision. Together, the expert guidance pro-
vides a general basis of care for Gaucher patients regardless of the
type of therapy. It is recommended that patients be thoroughly evaluat-
ed at the start of any treatment and regularly thereafter. The nature of
the assessments, particularly the radiological ones, will, to a certain ex-
tent, be dependent on local resources and their availability, which vary
from country to country. Evaluation and management of Gaucher dis-
ease should be initiated and supervised by a physician knowledgeable
about Gaucher disease. It is generally recommended that patients
Table 2
Eliglustat dosing with concomitant use of CYP2D6 and/or CYP3A inhibitors and inducers based on predicted CYP2D6 metaboliser status (tabulated version of SmPC guidance).
Potential interacting substances Extensive or intermediate metabolisers Poor metabolisers
CYP450 inhibitors Examples (list is not exhaustive) Effect on eliglustat exposure Recommendation
Effect on eliglustat 
exposure Recommendation
CY
P2
D
6 
in
hi
bi
to
rs Strong CYP2D6 inhibitor
Paroxetine, fluoxetine, bupropion, 
quinidine
C
max
: 7.3–fold ↑
AUC0–12 : 8.9–fold ↑
(eliglustat 84 mg twice daily + 
paroxetine 30 mg once daily)
Consider eliglustat 
84 mg once daily No data
Standard dose*
(84 mg once daily)
Moderate CYP2D6 
inhibitor
Duloxetine, terbinafine, 
moclobemide, mirabegron, 
cinacalcet, dronedarone
Predicted up to 4–fold ↑ Caution No data Standard dose*(84 mg once daily)
CY
P3
A
 in
hi
bi
to
rs
Strong CYP3A inhibitor
Clarithromycin, telithromycin
ketoconazole, itraconazole, 
posaconazole, voriconazole,
indinavir, lopinavir, ritonavir, 
saquinavir, telaprevir, tipranavir, 
boceprevir, conivaptan, cobicistat
C
max
: 3.8–fold ↑
AUC0–12 : 4.3–fold ↑
(eliglustat 84 mg twice daily 
+ ketoconazole 400 mg once
daily)
Caution
Predicted:
C
max
: 4.3–fold ↑ 
AUC0–24 : 6.2 fold ↑
Contraindicated
Moderate CYP3A 
inhibitor
Erythromycin, ciprofloxacin, 
fluconazole, diltiazem, verapamil, 
aprepitant, atazanavir, darunavir, 
fosamprenavir,
imatinib, cimetidine
Predicted up to 3–fold ↑ Caution
Predicted:
C
max
: 2.4–fold ↑
AUC0–24 : 3–fold ↑
Not recommended
Weak CYP3A inhibitors
Amlodipine, cilostazol, 
fluvoxamine, goldenseal, 
isoniazid, ranitidine, ranolazine
No data Standard dose (84 mg twice daily ) No data Caution
Grapefruit products Can increase levels Avoid Can increase levels Avoid
CY
P2
D
6 
+
 C
Y
P3
A
 
in
hi
bi
to
rs
 Strong or moderate 
CYP2D6 inhibitor PLUS
Strong or moderate 
CYP3A inhibitor
See above
Predicted:
Cmax : up to 17–fold ↑
AUC0–12 : up to 25–fold ↑
Contraindicated No data
See above for strong
or moderate CYP3A
inhibitors in poor
metabolisers
CY
P3
A
in
du
ce
rs
Strong CYP3A inducer
Rifampicin, rifabutin
carbamazepine, phenobarbital, 
phenytoin, St. John’s wort
85% decrease
(127 mg twice daily eliglustat + 
600 mg once daily rifampicin)
Not 
recommended
95% decrease
(84 mg twice daily
eliglustat + 600 mg once
daily rifampicin)
Not recommended
*The Summary of Product Characteristics (SmPC) does not provide specific guidance on the eliglustat dose for poor metaboliser s taking a strong or moderate CYP2D6 inhibitor. The guidance only identifies when the standard dose should be modified due to 
potential interaction. Thus, the standard dose for poor metabolisers (84 mg once daily) is recommended. Since the CYP2D6 pathway is already non–functional in poor metabolisers and they are entirely dependent upon the CYP3A pathway for eliglustat 
metabolism, taking a CYP2D6 inhibitor is of no consequence in these patients. AUC: area under the curve.
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should be evaluated by an expert offering specialized investigations
for assessing Gaucher disease at least once each year.
For the patient choosing between eliglustat and enzyme therapy, it
is essential that there is an informed consensus between patient and
physician to consider social, familial, professional, and psychological
factors, in the context of the patient's eligibility based on CYP2D6
genotyping, comorbidities, and potential for drug interaction set out in
detail below. An algorithm to determine eligibility for eliglustat therapy
is provided in Fig. 1.
4.1. CYP2D6 genotyping
For patients who wish to be considered for eliglustat therapy, to
predict their CYP2D6 metaboliser status and appropriate dosing,Table 3
Other potential drug interactions with eliglustat.
Drug class or drug name Examples
Agents whose concentrations may be increased by eliglustat:
P-gp substrates Digoxin, colchicine, dabigatran, phenytoin, pravastatin
CYP2D6 substrates Metoprolol, tricyclic antidepressants
(e.g. nortriptyline, amitriptyline, imipramine,
and desipramine), phenothiazines,
dextromethorphan, atomoxetine
Antiarrhythmic agents:
Class IA antiarrhythmic drugs Quinidine
Class III antiarrhythmic drugs Amiodarone, sotaloldetermination of the CYP2D6 genotype by testing a blood sample at a
nationally accredited laboratory is obligatory. Eliglustat is approved in
the European Union for adult patients who are predicted to be extensive,
intermediate or poormetabolisers. Eliglustat is not approved for the small
subset of patients in whom genotyping indicates CYP2D6 ultra-rapid and
indeterminate metabolism, since these patients may not reach adequate
eliglustat concentrations to achieve a therapeutic effect. Local Sanoﬁ
Genzyme representatives can be contacted for information about suitably
accredited local or central laboratories for CYP2D6 genotype testing in
constituent European countries.
4.2. Concomitant medications
Once CYP2D6 metaboliser status has been predicted from CYP2D6
genotyping to be extensive, intermediate, or poor, concomitantEffect on concomitant agent's
exposure
Recommendations for use concomitantly with
eliglustat
Digoxin: Cmax: 1.7-fold ↑
AUClast: 1.5-fold ↑
(eliglustat 127 mg twice daily +
single 0.25 mg dose of digoxin)
Lower doses of the P-gp substrate drug and
titration to therapeutic effect may be required
Metoprolol: Cmax 1.5-fold ↑
AUC: 2.1-fold ↑
(eliglustat 127 mg twice daily +
single 50 mg dose of metoprolol)
Lower doses of the CYP2D6 substrate drug and
titration to therapeutic effect may be required
NA Avoid eliglustat
NA Avoid eliglustat
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concomitant use of eliglustat with other drugs also metabolised by
CYP2D6 and CYP3A (Tables 2 and 3). In addition to the examples of
concomitant medications shown in these tables, treating physicians
should consult the Summary of Product Characteristics of the required
medication. Further sources of information include appropriate drug
interaction databases (for example, Stockley's Drug Interactions, 8th
edition at https://ilmufarmasis.ﬁles.wordpress.com/2011/07/stockley-
drug-interaction-2008.pdf or the University of Washington Drug
Interaction Database at http://didb.druginteractioninfo.org). Several
drug interaction databases are available electronically. However, the
physician should verify the quality and reliability of the database and
preferably should use one that is familiar and that allows for correct
interpretation of the data obtained.4.3. Pregnancy, lactation, and fertility
Currently, no data are available on the use of eliglustat in pregnant
women. So far, animal studies do not suggest harmful effects with re-
spect to reproductive toxicity. Women should avoid eliglustat during
pregnancy and should be instructed to consult a Gaucher disease physi-
cian if they become pregnant while taking the drug. It is not known
whether eliglustat or its metabolites are excreted in human milk,
though pharmacodynamic and toxicological studies have shown
eliglustat excretion in the milk of animals. The eliglustat product label
recommends deciding whether to discontinue breast-feeding or to
discontinue/abstain from eliglustat therapy after weighing the beneﬁts
of breast-feeding for the child and the beneﬁts of therapy for the
woman. Given that enzyme therapy during pregnancy and lactation
has been shown to reduce complications of Gaucher disease without
associated congenital defects or adverse effects [41–44], it is prudent
for pregnant or breastfeeding women to use enzyme therapy. It is not
known whether eliglustat has effects on male fertility in humans, al-
though, when given in very high doses (10-fold greater than predicted
human exposure) to rats, seminiferous epithelial degeneration and
segmental hypoplasia of the testes and reversible inhibition of sper-
matogenesis were observed [1].Adults  with type 1 Gaucher disease
CYP2D6 extensive, intermediate, or poor meta
a
 Congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, vent
b
 Class IA (e.g. quinidine) and Class III (e.g. amiodarone, sotalol)
Consider enzyme 
replacement 
therapy
No
Yes
Will likely comply with oral therapy?No
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Fig. 1. Algorithm for eliglustat eligibility in4.4. Cardiac status
A cardiac evaluation at baseline, including an electrocardiogram
(ECG), is already recommended in the ICGG Gaucher management rec-
ommendations [4]. When considering eliglustat, the ECG has additional
relevance as ameans to exclude underlying cardiac disease, and a cardi-
ologist should be consulted if ECG changes or abnormalities are detect-
ed or suspected. The potential for adverse effects of eliglustat on cardiac
conduction and repolarization requires substantially increased plasma
concentrations (i.e. 11-fold the exposure at therapeutic doses), which
may only be achieved through an overdose or a severe interaction
with other medicationsmetabolised by CYP2D6 and/or CYP3A. It is cur-
rently recommended to avoid the use of eliglustat in patients with cer-
tain cardiac conditions, in particular those predisposing to arrhythmias
(e.g. recent acutemyocardial infarction, ventricular arrhythmia, long QT
syndrome, bradycardia, heart block, congestive heart failure) and in
combination with Class IA and Class III antiarrhythmic medicinal prod-
ucts (Table 3). Use of eliglustat in these cardiac conditions has not been
studied in clinical trials. Although no signiﬁcant PR, QRS and QTc
increases were seen in a thorough ECG study of healthy volunteers
[45], more data are needed to evaluate the effects (or lack thereof) of
eliglustat on cardiac conduction in these patients in the real world
setting. Furthermore, cardiac examination, including ECG, would be
prudent in patients taking a high number of concomitant medications
(e.g. more than 4 or 5 drug classes), because potential drug interactions
in this setting would be difﬁcult to predict. Here, an opinion from and
involvement of a cardiologist should be considered.
4.5. Renal and hepatic status
Eliglustat has not been studied in patients with renal or hepatic im-
pairment, and so no dose recommendations are offered in the product
label, but generally the drug should be used with extreme caution, if
at all, in such patients. Eliglustat is principally metabolised by the liver
and is primarily excreted in faeces and to a lesser extent in urine.
Given theproven effectiveness of enzyme therapy and the absence of ef-
fects on kidney and liver function, it is prudent to use enzyme therapy in
patients with renal or hepatic impairment until satisfactory data haveboliser? 
ricular arrhythmia.  
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tions. Similarly, no data are available in patients infected with hepatitis
B or C virus or human immunodeﬁciency virus (HIV). In the ﬁrst two
diseases, reduced capacity of the liver to metabolise eliglustat is a
concern. Eliglustat therapy can be considered in those without manifest
hepatic impairment, provided there is close clinical monitoring of serum
liver-related tests during treatment with concomitant medications.
4.6. Special populations
A few special populations warrant consideration. Children were ex-
cluded from the clinical trials and only two adolescents were enrolled. A
paediatric trial is planned to assess the efﬁcacy and safety of eliglustat
use in children and adolescents. Likewise, only a small number of pa-
tients aged 65 years and over were enrolled in the clinical trials and
the efﬁcacy and safety of eliglustat in these patients was comparable
to patients younger than 65 years. Particular attention should be given
to treating patients in this older group due to the high probability of
co-morbidities and use of medications. Since the drug contains lactose
as an excipient, patients with rare hereditary problems of galactose in-
tolerance, lactase deﬁciency or glucose-galactose malabsorption should
not take eliglustat [1].
4.7. Recommendations for initial assessment
1. To determine any patient's eligibility for eliglustat treatment based
on his or her CYP2D6 metaboliser status, CYP2D6 genotyping is
mandatory. Eliglustat is extensively metabolised by CYP2D6, and, to
a lesser extent, by the CYP3A isozyme of the cytochrome P450
pathway.
2. It is essential to assess concomitant use of medications or herbal sup-
plements (including grapefruit products and other fruits that inhibit
CYP3A) that might affect CYP2D6 and CYP3A metabolism (Tables 2
and 3).
3. Dosing of eliglustat is based on the patient's CYP2D6 metaboliser
status andmodiﬁed according to chronic use of concomitantmedica-
tions also metabolised by CYP2D6 and CYP3A.
4. Screening for pregnancy, lactation, or intent to become pregnant is
required, as eliglustat should be avoided during pregnancy and
lactation.
5. Screening for cardiac, hepatic, and renal disease is required, as
eliglustat is not recommended or should be used with caution in
patients with these conditions.
6. Eliglustat is a capsule taken once or twice daily. It is important to
assess the patient's ability to adhere strictly to daily oral treatment.
7. Treatment for Gaucher disease should be initiated and supervised by
a physician with practical experience and familiarity with Gaucher
disease.
5. Ongoing monitoring of patients taking eliglustat
In addition to existing recommendations for the ongoingmonitoring
of haematological, visceral, skeletal, and biochemical parameters in type
1 Gaucher disease [4], guidance speciﬁc to monitoring patients on
eliglustat therapy is provided below.
5.1. Clinical response to eliglustat
As shown in Table 1, eliglustat improves haematological and visceral
disease parameters in previously untreated patients with type 1
Gaucher disease [27–29,31,34] and maintains haematological, visceral
and bone parameters in patients whose disease has been stabilised by
recent prior treatment with ERT [32]. Currently, there are no data which
indicate that switching from eliglustat to ERT, or vice versa, will result in
improvement in patients who do not achieve or maintain therapeutic
goals for haemoglobin concentration, platelet count or spleen or livervolumes within the expected time frames deﬁned by Pastores et al. [3].
However, such a stratagem seems reasonable given the comparatively
limited experience with eliglustat to date. Before changing therapies,
patients should be thoroughly re-assessed including consideration of
pre-treatment indicators of irreversiblemanifestations, concurrent illness
or pregnancy, and the possibility of medication non-adherence or
undisclosed concomitant medications. Any change of treatment must
be prescribed after a complete and rigorous evaluation of the disease,
including clinical and biological evaluation, biomarkers, and imaging —
otherwise it will be difﬁcult to attribute or not a complication to the
new treatment.
When switching from ERT to eliglustat, in clinical trials there was no
wash-out period between stopping ERT and starting eliglustat. It is thus
reasonable to start eliglustat within 2 weeks after the last ERT infusion.
There are no data to indicate antibody development to eliglustat and, to
our knowledge, such a phenomenon has not been reported. However,
since eliglustat is a small, orally active molecule and does not depend
on protein targeting to the macrophage system for its mode of action,
it may provide a useful alternative for patients who develop infusion re-
actions and/or attenuated therapeutic responses to enzyme therapy as a
result of antibody formation. When switching patients from miglustat
to eliglustat, it will be important to evaluate and document any adverse
events, particularly neurological, prior to the switch, because unwanted
effects on the nervous system, such as tremor or peripheral neuropathy,
are side effects of miglustat and could persist after the drug is stopped.
As with any newly approved drug, attention to adverse events and
monitoring for longer-term complications are important clinical
responsibilities as well as regulatory obligations. In a pooled analysis
of two randomized controlled trials and one 4-year clinical study with
a total of 152 patients ages 16–69 years who received eliglustat for a
median duration of 51.9 weeks (range 0.1 to 210.9 weeks), adverse
reactions reported in N2% of the patients were headache, nausea,
diarrhoea, abdominal pain, ﬂatulence, arthralgia, and fatigue [46]. In
the placebo-controlled pivotal trial of eliglustat, incidences of diarrhoea
and abdominal pain were reported to be higher with placebo than with
eliglustat [29].
5.2. Concomitant medications
Assessment of concomitant medications (and intake of grapefruit
products) that affect CYP2D6 and CYP3A metabolism at each visit is
essential, because dosing of eliglustat is based on CYP2D6 metaboliser
status and modiﬁed according to chronic use of concomitant medica-
tions also metabolised by CYP2D6 and CYP3A (Tables 2 and 3). Patients
should be instructed to inform other treating physicians that they
are taking eliglustat and that it may have interactions with drugs
metabolised through these pathways. Where concomitant prescribing
is necessary, required medications should be evaluated for potential in-
teractions. Patients should also be advised to consult with a physician
before use of any “over-the counter” medication, herbal substances,
and any medication not routinely prescribed.
5.3. Medication adherence
Unlike ERT, where infusions are commonly performed in a clinical
setting and staff can monitor adherence to therapy, patients will be
responsible for taking eliglustat each day. Physicians will need to ask
patients about medication adherence at regular visits and emphasize
the importance of taking eliglustat as directed.
Monitoring of eliglustat concentrations in blood is not useful for
routine assessment of medication adherence due to the very rapid me-
tabolism of eliglustat. However, there may be unusual circumstances
where measurement of eliglustat blood levels would be indicated,
such as in the face of highly divergent extremes of body mass and in
cases of accidental co-exposure, suspected toxicity (e.g. cardiac events
or arrhythmias), use of concomitant medications without known
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the patient otherwise unexplained. Such testing is available from the
manufacturer of the drug (Sanoﬁ Genzyme) and should be considered
on a case-by-case basis. When monitoring eliglustat blood concentra-
tions, it would be essential to record the time since the last eliglustat
dose was taken to judge the effect of metabolism.
5.4. Cardiac status
Routine ECG for patients taking eliglustat is not required as eliglustat
is not predicted to cause increases in ECG intervals at therapeutic doses.
If a PR, QRS or QTc prolongation is suspected or there are doubts
regarding a patient's ECG ﬁndings, a cardiologist should be consulted
for cardiac evaluation.
5.5. Surgery
As coagulation abnormalities due to disease-related impaired
production and chronic consumption of coagulation factors may occur
even in ERT-treated Gaucher patients, evaluation for coagulation abnor-
malities should be routine, especially prior to surgical, dental, and
obstetric procedures [47]. For patients taking eliglustat, physicians
should also consider the potential for drug interactions between
eliglustat and medications administered during surgical procedures. In
emergent situations, it would be prudent temporarily to stop treatment
with eliglustat.
5.6. Recommendations for ongoing monitoring
1. The frequency of monitoring of Gaucher disease patients is
dependent upon whether the patient has achieved therapeutic
goals [3].
2. Patients taking eliglustat who do not achieve or maintain therapeutic
goals within the expected time frames deﬁned by Pastores et al. [3],
should be thoroughly re-assessed and consideration given to switching
to ERT.
3. It is important to assess concomitant use of medications and herbal
supplements that affect CYP2D6 and CYP3A metabolism (including
grapefruit and other fruit products that inhibit CYP3A) at every
visit, because dosing of eliglustat is based on the patient's CYP2D6
metaboliser status andmodiﬁed according to chronic use of concom-
itant medications also metabolised by CYP2D6 and CYP3A. Patients
should consult their physicians before taking any new medication.
4. Where there is doubt as to whether the patent is taking the doses as
instructed, they should be asked speciﬁcally about their adherence to
prescribing guidance (i.e. compliance).
6. Summary
As a ﬁrst-line therapy for type 1 Gaucher disease, eliglustat offers
eligible patients a convenient, daily, oral therapy as an alternative to en-
zyme infusions. It is essential that Gaucher disease physicians carefully
assess individual patients to determine their appropriateness for this
oral therapy as set out in Fig. 1 and continue to monitor their response
to eliglustat and use of concomitant medications to ensure the best
possible outcome.
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